I need to check if there's enough substantive content. The filing includes financial statements with balance sheet data - cash and cash equivalents of $150,811 thousand, short-term investments of $478,976 thousand, etc. This is well over 150 words of substantive content. However, the filing text cuts off mid-way. I'll work with what's available, being careful to only state what's confirmed in the source.

Summit Therapeutics Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 4, 2026, disclosing condensed consolidated financial statements and related information.

Key Highlights

  • Cash and cash equivalents: $150,811 thousand as of September 30, 2026, compared to $225,266 thousand as of December 31, 2025, according to the filing.
  • Short-term investments: $478,976 thousand as of September 30, 2026, down from $488,182 thousand at December 31, 2025, per the balance sheet.
  • Shares outstanding: 799,763,918 shares of common stock, par value $0.01 per share, as of October 30, 2026, the filing reported.
  • Filer classification: The company is designated a large accelerated filer, not a smaller reporting company or emerging growth company, according to the cover page.
  • Key product candidate: The filing identifies ivonescimab as the principal clinical-stage asset, developed under a License Agreement referenced throughout the document.

Summit Therapeutics Reports September 30, 2026 Financial Position

Summit Therapeutics Inc. (NASDAQ:SMMT), headquartered at 601 Brickell Key Drive, Suite 1000, Miami, FL, filed its Form 10-Q for the quarterly period ended September 30, 2026. The filing presents unaudited condensed consolidated financial statements, covering the balance sheet, statements of operations and comprehensive loss, statements of stockholders' equity, and statements of cash flows, together with accompanying notes.

According to the condensed consolidated balance sheet, the company held cash and cash equivalents of $150,811 thousand as of September 30, 2026, a decrease from $225,266 thousand reported at December 31, 2025. Short-term investments stood at $478,976 thousand at the end of the third quarter, compared to $488,182 thousand at year-end 2025. Restricted cash remained at $316 thousand at both dates, the filing disclosed.

The filing states that the company's primary clinical-stage candidate is ivonescimab, which is being developed under a License Agreement. The company noted, among its forward-looking disclosures, uncertainty around "our ability to raise sufficient additional funds to make payments under the License Agreement, and fund ongoing operations and capital needs." The filing also references AstraZeneca's ownership and contractual rights as a factor affecting the company and its stockholders. All forward-looking statements in the filing are the company's own and are subject to its cautionary language as described in the document.

What Was Disclosed

Summit Therapeutics filed its Form 10-Q for the quarter ended September 30, 2026, reporting cash and cash equivalents of $150,811 thousand, short-term investments of $478,976 thousand, and 799,763,918 shares of common stock outstanding as of October 30, 2026.